Journal of Oncological Sciences最新文献

{"title":"Spirituality, A Method of Coping with Depression in Cancer Patients Who Received Chemotherapy in the Southwest of Turkey (PRAYER Study)","authors":"O. Tanrıverdi","doi":"10.37047/jos.2019-73128","DOIUrl":"https://doi.org/10.37047/jos.2019-73128","url":null,"abstract":"options, cancer is still the most significant health problem and one of the most prominent causes of death.1 During cancer diagnosis, treatment, and follow-up processes, cancer patients have to overcome either symptoms of their diseases or adverse effects of their therapies. If these symptoms combine with the fear of death and unhealed feeling, harmony with therapy and quality of life get worse. This leads to curiosity and fear in patients, thus deteriorating their physical and mental health.1-3","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of Atrial Myxoma and Gastrointestinal Stromal Tumor","authors":"H. Kaya, Yusuf Ilhan, S. Goksu, Ahmet Bodur, A. Tatlı, Gulay Ozbilim, H. Coşkun","doi":"10.37047/jos.2019-71885","DOIUrl":"https://doi.org/10.37047/jos.2019-71885","url":null,"abstract":"GISTs may be present in all parts of the gastrointestinal tract, but most often in the stomach (50%) and the small intestine (25%). In addition, the tumor can rarely be located in the colorectal (10%), omentum/mesentery (7%), and esophagus (5%).5 GISTs of 2 cm or less are typically asymptomatic and incidentally detected during surgery, radiology, or endoscopy for any other reason. The most common symptoms are abdominal pain, gastrointestinal bleeding, anemia, abdominal mass, dyspeptic complaints, and dysphagia.6 Most of the primary cardiac tumors (80%) are benign, and the most common benign heart tumor is atrial myxoma. Although myxomas may develop from all cardiac cavities, they are sporadic tumors and most commonly localized in the left atrium (75%). These tumors, which can be seen in all ages and more frequently in women, may occur with cerebral or peripheral embolism findings, and patients J Oncol Sci.2020;6(2):119-22","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"119-122"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Pemetrexed-Based Therapy in Advanced Lung Adenocarcinoma with Targetable Driver Mutation: A Real-Life Experience","authors":"B. Bilgin, Ş. Yücel, Ülkü Yılmaz","doi":"10.37047/jos.2020-73476","DOIUrl":"https://doi.org/10.37047/jos.2020-73476","url":null,"abstract":"cer-related deaths.1 Adenocarcinoma is the most common and the most investigated subtype among all the histological groups of lung cancer. Approximately 25% of patients with advanced adenocarcinoma have targetable driver mutations. This rate of occurrence is higher in non-smokers, young and female patients. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most common type of targetable driver mutations in nonsmall cell lung cancer (NSCLC). Besides, mutations in ROS-1, c-MET, B-RAF, and cErbB2 may occur rarely. Recently, there have been many therapeutic advances like the development of targeted therapy and the use of immune-checkpoint inhibitors for the treatment of lung cancer, especially adenocarcinoma subtype. However, chemotherapy remains an indispensable treatment option in advanced lung cancer. Pemetrexed, a multitargeted antifolate chemotherapy agent, was found to be effective in patients with lung adenocarcinoma as the first-line, second-line and maintenance therapy.2-4 Pemetrexed was granted conditional approval by the Food and Drug Association (FDA) for several steps of non-squamous non-small cell lung cancer (NSCLC) treatment. J Oncol Sci. 2020;6(1):43-8","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"43-48"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and Biological Mechanisms of Apoptosis and its Detection Techniques","authors":"Suganya Chinnasamy, F. Zameer, K. Muthuchelian","doi":"10.37047/jos.2020-73477","DOIUrl":"https://doi.org/10.37047/jos.2020-73477","url":null,"abstract":"the end of indications of life and is caused by functional irregularity. Cell death is genetically controlled and can be categorized into programmed, such as apoptosis and autophagy, and unprogrammed, such as necrosis. Apoptosis is an active self-destruction process, which is influenced by a diversity of stimuli that induce highly similar structural changes. These morphological changes are chromatin build-up, cytoplasmic shrinkage, zeiosis and the arrangement of apoptotic bodies inside the nucleus. The concluding phase of apoptosis is characterized by cytoplasmic membrane fragmentation and phagocytosis of debris by macrophages or adjacent cells. Figure 1 illustrates typical changes in the cells undergoing apoptosis or necrosis and the possible differences are tabulated in Table 1. Death by apoptosis is differentiated from death by necrosis by the absence of inflammatory responses. Early in 1972, these observations were reported by Kerr et al. but were less significant in those days.1 However, from embryogenesis to aging and from the normal tissue homeostasis to many diseases, apoptosis has been found to occur in various life stages and has become a field of importance in developmental biology, biogerontology, and cancer research. Malfunctioned apoptotic cascade may lead to several diseases like cancer due to its decreased rate and causes strokes and neurodegenerative disorders such as Alzheimer’s, Huntington and Parkinson’s diseases in an exaggerated state. Table 2 presents the timeline of cell death research.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"49-64"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer","authors":"H. Demir, I. Beypınar, M. Baykara","doi":"10.37047/jos.2020-75476","DOIUrl":"https://doi.org/10.37047/jos.2020-75476","url":null,"abstract":"Nearly one-fourth of the patients with NSCLC are diagnosed with locally advanced stage (stage III) and have a poor prognosis.4 For this condition, two treatment choices may be offered, induction chemotherapy followed by surgery or concurrent chemoradiation therapy.5,6 Nevertheless, even with advanced surgical techniques and postoperative consolidation chemotherapies, the local recurrence rates are 20-40%.7","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"96-102"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing Geriatric Oncology Patients from the Spread of COVID-19","authors":"A. I. Yasin, P. Soysal","doi":"10.37047/jos.2020-76410","DOIUrl":"https://doi.org/10.37047/jos.2020-76410","url":null,"abstract":"mortality from cancer occur in patients ≥65 years of age.1 The care of older patients constitutes an integral part of the everyday practice for an adult oncologist. Now it is known that COVID-19 infection has higher mortality in older patients and especially in those with chronic comorbidities.2 Cancer patients and especially old cancer patients create the most critical risk group in existing risk groups. In addition to aging, cancer itself and its treatments like chemotherapy, immunotherapy, and oncologic surgeries also weaken the immune system.3","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"2 1","pages":"131-132"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69818463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies","authors":"Ece Esin,&nbsp;İrem Bilgetekin,&nbsp;Fatma Buğdaycı Başal,&nbsp;Ayşe Ocak Duran,&nbsp;Umut Demirci,&nbsp;Berna Öksüzoğlu","doi":"10.1016/j.jons.2019.09.002","DOIUrl":"10.1016/j.jons.2019.09.002","url":null,"abstract":"<div><h3>Aim</h3><p>In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3.</p></div><div><h3>Material and Method</h3><p>Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed.</p></div><div><h3>Results</h3><p>A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10–217 months). Median survival was 91.4 months (58.9–123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04.</p></div><div><h3>Conclusions</h3><p>According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials.</p></div>","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"5 3","pages":"Pages 96-99"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jons.2019.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48090744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status","authors":"Abdullah Sakin ,&nbsp;Suleyman Sahin ,&nbsp;Muhammed Mustafa atci ,&nbsp;Cumhur Demir ,&nbsp;Nurgul Yasar ,&nbsp;Caglayan Geredeli ,&nbsp;Sener Cihan","doi":"10.1016/j.jons.2019.08.003","DOIUrl":"10.1016/j.jons.2019.08.003","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of this study was to evaluate the efficacy and tolerability of single-agent gemcitabine vs. capecitabine therapy in the second-line setting for metastatic Pancreatic Cancer (mPC) patients with poor performance status.</p></div><div><h3>Material and methods</h3><p>A total of 48 patients with mPC, who were followed and treated in oncology center between 2012 and 2017, were included. After a failure of first-line therapy, patients with an ECOG-PS 2 treated with capecitabine or gemcitabine monotherapy in the secondline setting were retrospectively analyzed.</p></div><div><h3>Results</h3><p>Of the 48 patients, 26(54.2%) were males and 22(45.8%) were females. The median age of the patients was 62 years(range, 31-82). Treatment regimens in the first-line setting were as follows; gemcitabine+cisplatin in 24(50%) patients, gemcitabine+nub-paclitaxel in 4(8.3%) patients, FOLFIRINOX in 8(16.7%) patients, FOLFOX in 8(16.7%) patients, and gemcitabine+oxaliplatine in 4(8.3%) patients. After progression on first-line therapy, 29(60.5%) patients were treated with capecitabine in the second-line setting, while 19(39.5%) patients were given gemcitabine. Median progression-free survival was found to be 4 months(95% CI,1.9-6.0) in patients receiving capecitabine compared to 2 months(95% CI, 0.5-3.4) in those treated with gemcitabine (p=0.271). Median overall survival was 6.0 months(95% CI, 2.0-9.9) in patients receiving capecitabine therapy versus 5.0 months (95% CI, 1.0-8.9) in those treated with gemcitabine monotherapy (p=0.353).</p></div><div><h3>Conclusions</h3><p>Optimal second-line treatment for mPC has not yet been established. In the present study, capecitabine monotherapy was compared to gemcitabine and it was found that they both had similar efficacy in the second-line treatment for mPC patients who were not eligible for combination chemotherapy regimen.</p></div>","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"5 3","pages":"Pages 85-89"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jons.2019.08.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41540243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of clinical and pathological features of gastrointestinal stromal tumors on overall survival and prognosis: Single center experience","authors":"Elif Merev ,&nbsp;Irfan Cicin","doi":"10.1016/j.jons.2019.10.003","DOIUrl":"10.1016/j.jons.2019.10.003","url":null,"abstract":"<div><h3>Aim</h3><p>Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. We aimed to evaluate the clinicopathological features of the patients in Thrace and improve our management.</p></div><div><h3>Material and Method</h3><p>In this retrospective study, 68 patients with a diagnosis of GIST referred to Trakya University Medical School Hospital between 1997 and 2015 were evaluated.</p></div><div><h3>Results</h3><p>The most common symptom was abdominal pain (38.2%) and the location was small-intestine (42.6%). Large masses had higher metastasis and relapse rate. The mean tumor size with relapse was 11.8 ± 3.8 cm meanwhile it was 6.5 ± 3.0 cm in non-relapsed patients (<em>p</em> = 0.01). The mean size of the tumor was 13.5 ± 4.4 in the metastatic group although this data was 8.8 ± 4.7 cm in the non-metastatic group (<em>p</em> = 0.01). With necrotic tumors, mitotic rate and size were higher. The mean mitosis count was 21.0 ± 3.6 in necrotic tumors and 7.2 ± 9.9 in non-necrotic tumors (<em>p</em> = 0.005). The mean size was 10.8 ± 5.0 cm in necrotic tumors and 5.6 ± 3.0 cm in non-necrotic tumors (<em>p</em> = 0.009). According to AFIP criteria, most of the patients were in the high-risk group (57.4%). Overall survival (OS) was longer in non-smokers and non-drinkers. Median OS was 80.16 months in non-smoker group (95% CI, 27.83–132.49) and 24.64 months (95% CI, 15.49–33.78) in the smoker group (<em>p</em> = 0.001). The median OS was 80.09 months in the non-drinker group (95% CI, 13.99–146.20) and 24.64 months (95% CI, 13.18–36.10) in drinker group (<em>p</em> = 0.05). Median OS in stomach GIST was 41.39 months, in small-intestine were 80.09 months and in the colon were 35.68 months (p = 0.032). Patients underwent surgery had longer overall-survival. Median OS was 80.09 months in patients undergone surgery and 16.98 months in patients had not been operated (p = 0.001). Overall survival was longer in GIST with mitotic rate &lt;5/50HPF than with &gt;5/50HPF. Median OS was 80.16 months in patients who had less than 5 mitosis and 39.22 months in higher mitotic rate (95% CI, 31.58–46.87) (p = 0.034). Overall survival was shorter in GIST with Ki-67 &gt; 5% than with 5%&gt;. Median OS was 80.16 months (95% CI, 28.80–49.65) in &lt;5% and 39.22 months (95% CI, 28.80–49.65) in 5%≤ Ki-67 (p = 0.004).</p></div><div><h3>Conclusions</h3><p>The most important factors about the survival and prognosis of GIST are location, size, mitotic rate, Ki-67, necrosis and surgery status. Using tobacco/alcohol may be related to survival. This study should be further investigated with extensive data.</p></div>","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"5 3","pages":"Pages 73-79"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jons.2019.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41952069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EDB","authors":"","doi":"10.1016/S2452-3364(19)30089-5","DOIUrl":"https://doi.org/10.1016/S2452-3364(19)30089-5","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"5 3","pages":"Pages ii-iii"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2452-3364(19)30089-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137205011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}